Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Key Points

• Recurrence rates are notably high even after achieving complete response to atezo/bev therapy.
• Patients with two or more prior HCC treatments are at a heightened risk for recurrence.
• The findings emphasize the need for vigilant post-therapy surveillance in these patients.
• Surveillance is critical for improving management and outcomes after treatment.